ATE365173T1 - Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine - Google Patents

Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Info

Publication number
ATE365173T1
ATE365173T1 AT00932412T AT00932412T ATE365173T1 AT E365173 T1 ATE365173 T1 AT E365173T1 AT 00932412 T AT00932412 T AT 00932412T AT 00932412 T AT00932412 T AT 00932412T AT E365173 T1 ATE365173 T1 AT E365173T1
Authority
AT
Austria
Prior art keywords
sub
line
formulae
amino acid
modified form
Prior art date
Application number
AT00932412T
Other languages
English (en)
Inventor
Richard Gordon
Deborah Moorad
Bhupendra Doctor
Gregory Garcia
Original Assignee
Us Army Med Res Mat Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army Med Res Mat Command filed Critical Us Army Med Res Mat Command
Application granted granted Critical
Publication of ATE365173T1 publication Critical patent/ATE365173T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00932412T 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine ATE365173T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13444699P 1999-05-17 1999-05-17

Publications (1)

Publication Number Publication Date
ATE365173T1 true ATE365173T1 (de) 2007-07-15

Family

ID=22463433

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932412T ATE365173T1 (de) 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Country Status (9)

Country Link
US (3) US6573244B1 (de)
EP (1) EP1179010B1 (de)
JP (1) JP2003501012A (de)
AT (1) ATE365173T1 (de)
AU (1) AU772985B2 (de)
CA (1) CA2372304A1 (de)
DE (1) DE60035270D1 (de)
IL (1) IL146459A0 (de)
WO (1) WO2000069891A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6713444B1 (en) * 1999-05-14 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE10038511A1 (de) * 2000-08-08 2002-02-21 Bhs Corr Masch & Anlagenbau Längs-Bearbeitungs-Maschine für Wellpappe-Bahnen
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7350590B2 (en) * 2002-11-05 2008-04-01 Weatherford/Lamb, Inc. Instrumentation for a downhole deployment valve
EP2153848A3 (de) 2005-01-27 2010-07-21 The Regents of the University of California Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
US8658372B2 (en) * 2005-06-10 2014-02-25 The United States Of America, As Represented By The Secretary Of The Navy Affinity-based detection of biological targets
WO2007062060A2 (en) 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059693A (en) * 1976-06-11 1977-11-22 University Patents, Inc. Analgesic action of substance P
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
US5495047A (en) * 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
WO1993001165A2 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, compositions containing them and their use in therapy
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Also Published As

Publication number Publication date
US7375079B2 (en) 2008-05-20
DE60035270D1 (de) 2007-08-02
EP1179010A2 (de) 2002-02-13
WO2000069891A9 (en) 2002-07-04
EP1179010B1 (de) 2007-06-20
IL146459A0 (en) 2002-07-25
WO2000069891A3 (en) 2001-07-19
WO2000069891A2 (en) 2000-11-23
CA2372304A1 (en) 2000-11-23
US20050113304A1 (en) 2005-05-26
AU5013600A (en) 2000-12-05
US20060247176A1 (en) 2006-11-02
AU772985B2 (en) 2004-05-13
JP2003501012A (ja) 2003-01-14
US6573244B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
ATE365173T1 (de) Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
NZ520659A (en) Xylanase variants having altered sensitivity to xylanase inhibitors caused by mutations in the lid region
DE69434817D1 (de) Protease varianten
ATE199090T1 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
ATE168130T1 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
ATE245185T1 (de) Proteasen enthaltende bleichmittelzusammensetzungen
BR0113864A (pt) ácidos nucléicos tipo kcp isolados e suas proteìnas codificadas
DE69717474D1 (de) Durch cyclische aminosäuren oder cyclische hydroxysäuren substituierte benzamidinderivate und deren verwendung als antikoagulantien
ATE103632T1 (de) Enzymatische waschmittelzusammensetzung und verfahren zum stabilisieren der enzyme.
EA200200017A1 (ru) Терапевтическое средство с ботулиническим нейротоксином
PT94016A (pt) Processo para a producao de inibidores de proteinases
BRPI0407294A (pt) Protease da famìlia de peptidases s2a e/ou famìlia de peptidases s1e, sequência de ácido nucleico isolada, construção de ácido nucleico, vetor de expressão recombinante, célula hospedeira recombinante, método para produzir um polipeptìdeo, planta transgênica, ou parte de planta, animal transgênico não-humano ou produtos ou elementos dos mesmos, uso de pelo menos um polipeptìdeo, aditivo de ração animal, composição de ração animal, e, composição detergente
BR9909130A (pt) Variantes de protease de serina tendo substituições de amino-ácido
ATE228856T1 (de) Mittel für die steuerung von der zellaktivität
NO20005261L (no) Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning
DE69728869D1 (de) Von aminosauren und hydroxysauren substituierte benzamidinderivate und deren verwendung als antikoagulantien
ATE170868T1 (de) Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
ATE153670T1 (de) Peptidboronsäurederivate mit protease inhibierenden aktivität
ATE309264T1 (de) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
PT830130E (pt) Enzima de conversao de tnf-alfa
Burchacka et al. Phosphonic analogues of glutamic acid as irreversible inhibitors of Staphylococcus aureus endoproteinase GluC: an efficient synthesis and inhibition of the human IgG degradation
ATE92935T1 (de) Serinproteaseinhibitoren und isolierungsverfahren dazu.
BR9912519A (pt) Variantes estabilizadas de inibidor de subtilisina de streptomyces
WO2000069895A3 (en) Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties